Surrogate and Intermediate Endpoints in Randomized Trials: What's the Goal?
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 29440189.
- Also identified by DOI 10.1158/1078-0432.CCR-18-0183.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Establishing trial-level surrogacy of an intermediate endpoint for predicting survival benefit in future trials is extremely challenging because of the extrapolations required, but there are other useful drug development and patient management applications of intermediate endpoints. <i>Clin Cancer Res; 24(10); 2239-40. ©2018 AACR</i><i>See related article by Mushti et al., p. 2268</i>.
Medical subject headings
- Goals
- Progression-Free Survival